Human glioblastoma in mouse

Molecularly Targeted Vaccine Trials for Adult and Pediatric Gliomas

We have translated our laboratory discoveries into the following investigator-initiated, novel immunotherapy trials that are currently active in enrolling patients.

In NCT02549833 (IND 16794, Okada), we are evaluating whether vaccination of LGG patients with lysate derived from an allogeneic glioblastoma (GBM) cell line will induce T-cell responses against GBM-derived antigens, with our ultimate goal to inhibit transformation to GBM.

In NCT02924038 (IND 16927, Okada), we are evaluating whether varlilumab, a novel, agonistic monoclonal antibody against CD27 enhances induction of CTL responses against 10 GAAs included in the IMA950 vaccine in patients’ peripheral blood and tumors.

Furthermore, based on our recent identification of the H3.3.K27M neoantigen epitope, we recently implemented a multi-center pilot study to evaluate the safety, immunoreactivity and preliminary efficacy of a peptide vaccine targeting the H3.3 K27M epitope in children with H3.3K27M+ glioma through the Pacific Pediatric Neuro-Oncology Consortium (PNOC; NCT02960230; IND17070 Okada).

 

Who works on this project in the Okada Lab?